Surgery as an alternative to radiotherapy in early-stage nasopharyngeal carcinoma:innovation at the expense of uncertainty  

作　　者：Luo Huang Melvin L.K.Chua 

机构地区：[1]Division of Radiation Oncology,National Cancer Centre Singapore,Singapore 169610 [2]Division of Radiation Oncology,Chongqing University Cancer Hospital and Institute,Chongqing 400030,P.R.China [3]Division of Medical Sciences,National Cancer Centre Singapore,Singapore 169610 [4]Oncology Academic Clinical Programme,Duke-National University of Singapore Medical School,Singapore 169857

出　　处：《Cancer Communications》2020年第2期119-121,共3页癌症通讯（英文）

基　　金：MC is supported by the National Medical Research Council Singapore Clinician-Scientist Award-#NMRC/CSA/0027/2018 and the Duke-NUS Oncology Academic Program Proton Research Program.

摘　　要：Radiotherapy(RT)has an unassailable track record as the backbone of treatment in nasopharyngeal carcinoma(NPC).Several reasons explain its dominance.Likewise to human papilloma virus-associated oropharyngeal squamous cell carcinoma,Epstein-Barr virus(EBV)-associated NPC is exquisitely sensitive to RT.Thus,huge leaps with technological advances in RT delivery over the past decades have led to substantial improvements in tumor control,while reducing debilitating late RT-induced complications[1,2].Innovations in this space continue to drive the enhancement of the therapeutic ratio of RT,with the goal of enhancing the quality of life(QoL)among long-term survivors[3].Therefore,there has not been any compelling reason to disrupt this timehonored convention of employing RT as the standard of care in NPC.

关 键 词：Early stage nasopharyngeal carcinoma resection SURGERY TOXICITIES 

分 类 号：R73[医药卫生—肿瘤]